Actively Recruiting
Comprehensive Analysis of Gut Microbiota Signatures in Metastatic Colorectal Cancer
Led by Sixth Affiliated Hospital, Sun Yat-sen University · Updated on 2025-12-31
300
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Colorectal cancer (CRC) is one of the most common and deadly cancers worldwide. About 1 in 4 people with CRC already have cancer spread (metastasis) when first diagnosed, and about half develop spread during their illness. Recent research shows that bacteria living in the gut and even within tumors might play an important role in how cancer spreads. The goal of this study is to better understand how bacteria might influence the spread of colorectal cancer. The main questions the investigators aim to answer are: Are there differences in bacteria between people whose cancer has spread and those whose cancer has not spread? Could certain bacteria help predict which cancers might spread? To answer these questions, the investigators will: Collect different types of samples from participants: Tumor tissue Normal tissue near the tumor Tissue from where cancer has spread Stool samples before surgery Study the bacteria in these samples using advanced testing methods Compare bacterial patterns between different groups People can take part in this study if they: Are between 18 and 75 years old Have colorectal cancer confirmed by doctors Have not taken antibiotics recently Do not have immune system problems This research may help us: Understand why some colorectal cancers spread Find new ways to predict which cancers might spread Develop better treatments for colorectal cancer
CONDITIONS
Official Title
Comprehensive Analysis of Gut Microbiota Signatures in Metastatic Colorectal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years
- Pathologically confirmed colorectal cancer
- Clearly defined clinical staging, including metastatic colorectal cancer (stage M1) and non-metastatic colorectal cancer (stage M0)
- Expected survival of at least 3 months
- Voluntary participation with signed informed consent
You will not qualify if you...
- Use of probiotics, antibiotics, or immunosuppressive agents within 1 month before surgery
- Preoperative complete intestinal obstruction or gastrointestinal perforation
- Intraoperative gastrointestinal perforation or tumor rupture
- Previous history of gastrointestinal surgery excluding colorectal cancer surgery, appendectomy, and cholecystectomy
- Concurrent severe gastrointestinal diseases such as inflammatory bowel disease
- Active systemic immune or infectious diseases including severe allergies, rheumatoid arthritis, systemic lupus erythematosus, viral hepatitis, or acquired immunodeficiency syndrome
- Concurrent unhealed primary malignant tumors
- Severe organ dysfunction or failure
- Other conditions deemed unsuitable for the study by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Sixth Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China, 510655
Actively Recruiting
Research Team
L
Lu Xiang'en
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here